Exosomes are cell-signalling vesicles being sold across aesthetics for skin rejuvenation, post-procedure recovery, and hair. The early clinical data is interesting but small and unstandardised, and no exosome product is approved for aesthetic use by the FDA or licensed for it in the UK. The gap between what is being claimed and what is proven, and lawful to claim, is where practitioners get caught.
What exosomes actually are
Exosomes are extracellular vesicles, roughly 30 to 150 nanometres across, released by cells as a way of talking to other cells. They carry proteins, lipids, and genetic material such as messenger RNA and microRNA. The theory in aesthetics is that vesicles harvested from cultured cells, often stem cells, deliver those signals into skin and prompt repair, collagen activity, and reduced inflammation.
In practice they reach the clinic in two forms. Topical serums applied after microneedling or laser, where the disrupted skin barrier is meant to improve uptake. And injectable or microneedled preparations, which is where the regulatory and safety stakes climb sharply. The biology is genuinely worth watching. The marketing has run a long way ahead of it.
What the clinical evidence supports
The honest summary is: promising early signals, no large standardised trials yet. The overview in the Aesthetic Surgery Journal sets out the mechanism and the small body of studies reporting improvements in hydration, elasticity, and wrinkle depth, particularly as an adjunct to microneedling and laser resurfacing. The same review is clear about the limits: small samples, short follow-up, heterogeneous products, and no standardisation of what is actually in the vial.
That last point is the one practitioners underweight. Two preparations both labelled "exosomes" can differ in source cell, isolation method, concentration, purity, and storage. There is no agreed potency standard, so a study showing benefit for one product does not transfer to the bottle a different supplier is selling you. Recent systematic reviews reach the same verdict from the opposite direction: positive associations for skin quality measures, paired with an explicit call for larger, standardised trials before firm clinical claims are reasonable.
So the evidence does not say exosomes do nothing. It says the data is early, the products are inconsistent, and confident before-and-after promises are not yet supportable from the literature.
Where the regulators draw the line
This is the part that turns a marketing question into a compliance one. The FDA's public safety notification on exosome products is unambiguous: no exosome product is FDA-approved for any use, products intended to treat or affect the structure or function of the body are regulated as drugs and biologics, and administering unapproved exosome products to patients violates federal law. The notification cites reported adverse events including blindness, infection, and tumour formation, almost all tied to injected, unapproved preparations.
The UK position runs on the same logic through different machinery. A product that makes a therapeutic or structure-and-function claim falls under medicines law and the remit of the MHRA, and no exosome product is licensed as a medicine for aesthetic use here. A human-derived biological product also raises sourcing, traceability, and safety obligations that a cosmetic serum does not. The line is the claim: market a product as repairing, regenerating, or treating, and you have very likely placed it inside medicines regulation, where none of these products hold a licence.
Advertising rules sit on top of that. Medicinal claims for unlicensed products, and unsubstantiated efficacy claims generally, are exactly what the advertising regulators act on. A clinic can be fully sincere about a treatment and still be non-compliant in how it advertises it.
What this means for your clinic
None of this requires a practitioner to reject exosomes outright. It requires the same discipline that protects you on every newer intervention.
- Separate the topical from the injectable. A post-procedure topical making cosmetic claims sits in a very different risk and regulatory bracket from an injected biological product. The injectable route is where the FDA's documented harms cluster and where UK medicines law bites hardest.
- Audit the claim, not just the product. "Supports skin recovery" is a different legal object from "regenerates tissue" or "treats scarring". The wording on your website and consent forms is what a regulator reads.
- Ask the supplier for the evidence on that product. Not exosomes in general. The specific preparation, its source, and its safety and efficacy data. No answer is an answer.
- Document consent honestly. Where evidence is early and approval absent, that has to be said plainly to the patient, not smoothed over.
This is the same evidence-and-compliance posture that the polynucleotides evidence picture called for: a real treatment, real early data, and marketing that needs reining in to what is defensible.
Getting this right is not caution for its own sake. Compliance gets you open. Reputation keeps you in business. The practitioners who survive each new trend are the ones who adopt on the evidence and advertise within the rules, which is the entire spine of From Regulation to Reputation, the structured route through UK aesthetic compliance before the licensing framework tightens further. The wider course catalogue sits alongside it for practitioners formalising their clinical footing.
FAQ
Are exosomes approved for aesthetic use?
No. The FDA has approved no exosome product for any use and regulates them as drugs and biologics, and no exosome product is licensed as a medicine for aesthetic use in the UK. Products are reaching clinics through marketing, not through regulatory approval, which is the central fact to hold onto.
Is it legal to offer exosome treatments in the UK?
It depends entirely on the product and the claim. A product making therapeutic or structure-and-function claims falls under medicines law and the MHRA's remit, where none are licensed for aesthetics. The JCCP and medicines and advertising rules all bear on this, so any practitioner considering exosomes needs specific regulatory advice on the exact product before offering it.
Does the evidence show exosomes work?
Early studies report improvements in hydration, elasticity, and wrinkle depth, often as an adjunct to microneedling or laser. The studies are small, short, and unstandardised, and the reviews consistently call for larger, standardised trials. The evidence supports continued study, not confident clinical promises.
Why is the injectable route higher risk?
The serious adverse events in the FDA's notification, including blindness, infection, and tumour formation, are overwhelmingly linked to injected, unapproved exosome products. Injecting an unstandardised biological product carries infection and immune risks that a topical does not, and it sits more squarely inside medicines regulation.
How should a clinic talk about exosomes to patients?
Plainly. State that the product is not approved or licensed for aesthetic use, that the evidence is early, and what is and is not known about the specific preparation. Honest consent protects the patient and protects you, and it is far easier to defend than a confident claim the literature does not yet support.